International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 123-127
PROGNOSTIC FACTORS IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT CHEMOTHERAPY
BÜLENT ALKAN1, BÜLENT KARABULUT1, ULUS A. ŞANLI1, VELİDDİN C. SEZGİN1, RÜÇHAN USLU1, NECMETTİN ÖZDEMİR1, ERDEM GÖKER1
Ege Üniversitesi Tıp Fakültesi İç Hastalıkları AD, İZMİR
Keywords: breast, cancer, survival, p53
Breast cancer is an important health problem. Many prognostic and predictive factors are being intensively investigated to determine most appropriate treatment option for patients with breast cancer. The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression. In this study, we have investigated impact of these prognostic factors on patient survival in patients with breast cancer who have received adjuvant AC (adriamycin, cyclophosphamide) chemotherapy. Median follow up time was 48 months. In this period, 5 patients had metastases. By Kaplan-Meier method, we have found that disease-free survival at two years was %97, at four years was %73.1. Median disease-free survival was 42.2 months. By log-rank method, we have found that p53 has negative impact on prognosis. This finding is compatible with current literature. Other factors were not found to be statistically important on prognosis.
BÜLENT ALKAN1, BÜLENT KARABULUT1, ULUS A. ŞANLI1, VELİDDİN C. SEZGİN1, RÜÇHAN USLU1, NECMETTİN ÖZDEMİR1, ERDEM GÖKER1
Ege Üniversitesi Tıp Fakültesi İç Hastalıkları AD, İZMİR
Keywords: breast, cancer, survival, p53
Breast cancer is an important health problem. Many prognostic and predictive factors are being intensively investigated to determine most appropriate treatment option for patients with breast cancer. The most important prognostic and predictive factors are axillary lymph node involvement, tumor size, hormone receptor status, c-erbB-2 and p53 expression. In this study, we have investigated impact of these prognostic factors on patient survival in patients with breast cancer who have received adjuvant AC (adriamycin, cyclophosphamide) chemotherapy. Median follow up time was 48 months. In this period, 5 patients had metastases. By Kaplan-Meier method, we have found that disease-free survival at two years was %97, at four years was %73.1. Median disease-free survival was 42.2 months. By log-rank method, we have found that p53 has negative impact on prognosis. This finding is compatible with current literature. Other factors were not found to be statistically important on prognosis.